7년째를 맞이하는 Next Generation Dx Summit은 폭넓은 토픽을 다루는 프로그램을 통한 새로운 정보 파악과 유익한 네트워킹 기회로, 세계 각지에서 800여명이 참가합니다. 임상진단에서 사업 전략에 이르기까지 다양한 분야를 다루는 올해 프로그램에는 암 예측 바이오마커, 동반진단, 감염증, Point-of-Care, 약국에서의 진단, 무세포 DNA(cfDNA), 상업화, 암 면역치료와 상환 등 다양한 토픽이 포함됩니다. 진단 분야의 중요 토픽을 폭넓게 다루는 Next Generaton Dx Summit은 급속히 진화하는 이 분야의 최신 발표를 듣고 개발 성과를 접할 수 있는 최적의 기회입니다.
쇼트코스 - 상세 아젠다 안내
지난 컨퍼런스 참가자 소감
"The Next Generation Dx Summit brings together key players from all facets of diagnostic development. Its format is very conducive to networking and
learning from the leaders in the field. This is a great meeting for anyone who is serious about pursuing diagnostic technologies anywhere from research to commercialization."
Program Director, Fluxion Biosciences
"The meeting was excellent, one of the best I have attended, and the standard of talks matched to the schedule across the board."
Vice President, Diagnostics, GlaxoSmithKline
"As we begin to move from a centralized lab to a point-of-care setting we have faced many challenges. It has been a very rewarding meeting with the leaders in policy making along with the leaders in development all in the same place."
Pathology, Graves Gilbert Clinic
"Great conference! Most up to date data. Perfect amalgamation between industry, labs, clinicians and regulatory bodies. Highly recommended!"
Clinical Microbiology Fellow, NIH
» 참가자 소감
Stories and Videos from Next Generation Dx Summit 2014
환자 이익의 최대화 실현：기술 혁신과 규제 준수의 양립
Moderator: Elaine Lyon, Ph.D., Medical Director, Molecular Genetics, ARUP (AMP 2014 President and Member, AMP Professional Relations Committee)
Jordan S. Laser, M.D., Medical Director, Pathology and Laboratory Medicine, North Shore Long Island Jewish Health System (Member, AMP Professional Relations Committee)
Jamie McDonald, MS, Licensed Genetic Counselor, Co-Director, HHT Center of Excellence; Assistant Professor, Department of Pathology, University of Utah
Stephen P. Day, Ph.D., IVD Consultant (Member, AMP Professional Relations Committee)
IMPACT OF PAMA REGULATIONS ON IVDS
Moderator: Bruce Quinn, M.D., Ph.D., Senior Health Policy Specialist, Foley Hoag LLP
The Impact of PAMA on Molecular Tests
Scott V. McGoohan, J.D., Vice President, Reimbursement & Scientific Affairs, American Clinical Laboratory Association
John F. Warren, Senior Director, McDermott+Consulting LLC
Donna Polizio, Associate Director, Government Accounts, Genomic Health
Paul W. Radensky, M.D., Partner, Health Products Regulation Group, McDermott Will & Emery LLP